HEALTHEQUITY, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HQY in the last 7 days.
HealthEquity (HQY) reported higher Q2 revenue and net income, raising full-year earnings guidance. Despite this, shares are down 8% over the past month, contrasting with a 5% 1-year and 41% 3-year total return. The stock's valuation is now under scrutiny, with a fair value estimate of $115.56, but it trades at a higher P/E ratio compared to industry peers.
HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.
HealthEquity reported Q2 revenue of $350.7M, up 8% YoY. Adjusted EBITDA rose 11% to $167M, with a record margin of 48%. HSA assets grew 14% to $37.9B. Net income increased 10% to $65.6M. The company raised fiscal 2027 guidance, citing strong execution and operating leverage.
Recent HQY coverage spans earnings, market movers and insider activity.
In the last 30 days, HQY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($798K). The most active reporter was DILLON ADRIAN T with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Guidance raise may support upside, but recent share price pullback suggests mixed sentiment.
Strong earnings and upbeat guidance suggest continued revenue growth and margin expansion.
Strong earnings beat and guidance raise suggest upside potential.
Earnings beat with slight guidance increase failed to meet investor expectations, triggering a sell‑off.
Positive earnings beat and upgraded price target may lift the stock.
AlphAI scores every news story that mentions HQY with an AI model for sentiment and relevance, and aggregates insider trades from HEALTHEQUITY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HealthEquity (HQY) reported higher Q2 revenue and net income, raising full-year earnings guidance. Despite this, shares are down 8% over the past month, contrasting with a 5% 1-year and 41% 3-year total return. The stock's valuation is now under scrutiny, with a fair value estimate of $115.56, but it trades at a higher P/E ratio compared to industry peers.
2 min readHealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.
3 min readHealthEquity reported Q2 revenue of $350.7M, up 8% YoY. Adjusted EBITDA rose 11% to $167M, with a record margin of 48%. HSA assets grew 14% to $37.9B. Net income increased 10% to $65.6M. The company raised fiscal 2027 guidance, citing strong execution and operating leverage.
2 min readHealthEquity (HQY) stock fell 8.6% this week despite beating earnings and revenue estimates for Q2. The company reported adjusted EPS of $1.24 on revenue of $350.7M, up 15.7% and 7.6% YoY, respectively. Investors expected stronger guidance, as the company only slightly raised its full-year revenue target and reiterated EPS guidance.
2 min readBarclays analyst Peter Warendorf maintained a Buy rating on Healthequity (HQY) with a $110 price target. Bank of America also has a Buy rating with a $125 target. Healthequity reported Q2 revenue of $350.73M and net profit of $65.64M, up from $325.84M and $59.85M last year.
1 min readHealthEquity Inc (HQY) shares rose 3.2% to $96.36 on August 28, 2026, despite a challenging week and month. The stock has a 9.2% increase over the past year and a 12.3% growth over three years. According to GF Value™, HQY is undervalued at $96.36, 9.2% below its estimated fair value of $106.08. The GF Score™ of 96/100 indicates strong performance, but insider activity shows $5.0M in sales over the past year with no recent buying.
2 min readHealthEquity (HQY) reported Q2 net income of $65.6M ($0.78 EPS) and revenue of $350.7M, beating estimates. A DCF model suggests 48% upside, valuing shares at $179, despite mixed market multiples. Full-year guidance is $4.66-$4.73 EPS on $1.41B-$1.42B revenue. Investors debate the durability of the company's free cash flow.
2 min readHealthEquity, Inc. reported Q2 2027 record adjusted EBITDA margins of 48% and 24% new HSA sales growth. The company raised fiscal 2027 revenue guidance to $1.411B–$1.421B and plans to roll out a next-gen app. Invested HSA assets increased 28% YoY. Management highlighted AI-driven cost reductions and Marketplace growth.
2 min readDILLON ADRIAN T sold 7,632 shares of HEALTHEQUITY, INC. (HQY) at an average of $104.61 ($104.47–$105.26, $0.80M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readHealthEquity (HQY) shares dropped 14% to $89.85 despite reporting higher Q2 profit. Net income rose to $65.644M ($0.78 per share) from $59.854M ($0.68 per share) year-over-year. Revenue increased 7.6% to $350.732M. Trading volume was 612,215 shares.
2 min read
